Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
M J CorkD ThaçiL F EichenfieldPeter D ArkwrightX SunZ ChenBolanle AkinladeS BoklageI GuilleminM P KosloskiM A KamalJ T O'MalleyN PatelN M H GrahamAshish BansalPublished in: The British journal of dermatology (2020)
These safety and efficacy results support the use of dupilumab as a continuous long-term treatment for children aged ≥ 6 to < 12 years with severe AD.